The combination of anti-PD-1 and anti-CTLA-4 therapy (nivo-ipi) has been officially approved by the US Food and Drug Administration (FDA) for the treatment of a variety of cancers, including colorectal cancer, hepatocellular carcinoma, and other cancers (23, 24). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.